Lorantis
Stage
Acquired | AcquiredAbout Lorantis
Lorantis is discovering and developing breakthrough products for the treatment of immunological and inflammatory diseases based on antigen-specific tolerance. The company's approach arises from the discovery of a new set of biochemical signalling pathways that regulate the action of T-cells. The company was acquired by Celldex Therapeutics in October 2005. (09/98
Latest Lorantis News
Feb 27, 2015
This website will be unavailable in minutes, due to an essential update. The update should take no longer than minutes. We apologize for any inconvenience caused. Retrieving Data You are a user. The feature you are trying to access Subscribers. Please Register to access this feature or log in if you are a Subscriber, or if you have already Registered. Please click the following link to register and submit an upgrade request, so that a member of our sales team can contact you to discuss your requirements. Please click the 'Request Upgrade' button to log your details so that a member of our sales team can contact you to discuss your additional requirements. Your request to access this feature is pending. You have already logged a callback request. A member of our team will contact you to discuss your access level. This feature is not yet available. We have already attempted to contact you following your recent request. We will try and call you again shortly but in the meantime please check that your contact details are correct and up to date or if you prefer please contact us. View My Contact Details Contact Us Retrieving... EP Vantage brings a fresh view on pharma and biotech with incisive daily analysis, powered by Evaluate Ltd. You are a subscriber to the full Evaluate Ltd. service. Click here to login to the subscribers' welcome page. Don't remind me again You are currently accessing our secondary server Although the site contains up to date data, some features are unfortunately not available on the secondary server. We apologise for any inconvenience this may cause. Close ECommerce Support If you would prefer to speak to a member of our sales team please call us on +44 (0)20 7377 0800 Alternatively, if you are experiencing problems with an existing order a member of our support team will be happy to assist you. Call +44 (0)20 7377 0800 Telephone lines are open Mon - Fri 9am - 5pm London Time. Alternatively, send an email to chrissie.pennock@evaluategroup.com Shopping Cart Fetching cart contents. Please wait. Please register your details with us to complete your purchase or click Login if you have already registered with us.
Lorantis Frequently Asked Questions (FAQ)
What is Lorantis's latest funding round?
Lorantis's latest funding round is Acquired.
Who are the investors of Lorantis?
Investors of Lorantis include Celldex Therapeutics and Abingworth.